The BioPharm Brief: AI, T-Cell Engagers, and Longevity Research

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, technology, and drug development. Today’s update looks at next-generation T-cell engagers in multiple myeloma, artificial intelligence (AI) in longevity research, and the digital infrastructure increasingly underpinning modern biopharma.

First, in drug development, GSK is expanding its interest in next-generation T-cell engagers, agreeing to acquire a trispecific TCE from Chimagen Biosciences for multiple myeloma. The program is expected to enter phase 1 trials in 2027, and GSK says its ability to engage T cells while simultaneously targeting 2 tumor-associated antigens could offer differentiated efficacy and safety. The deal highlights continued interest in refining T-cell engager approaches as developers look for ways to improve both activity and tolerability.

That focus on next-generation therapies connects with another area where technology is reshaping drug discovery: longevity research. Insilico Medicine is applying artificial intelligence and multiomic data to identify and evaluate targets associated with aging, while also exploring biomarkers that could help measure biological aging in clinical development. Recent work from the company illustrates how AI-generated hypotheses are increasingly moving toward clinical validation rather than remaining solely in the discovery phase.

And underpinning both of these trends is a broader transformation in biopharma technology infrastructure. As drug development becomes more data-intensive, information technology (IT) organizations are moving beyond traditional support roles toward systems designed around harmonized clinical data, interoperable data architectures, hybrid cloud environments, and AI. Those capabilities are becoming increasingly important for turning complex datasets into reusable, analysis-ready resources that can support development decisions.

These stories point to a common direction, in which biopharma innovation is increasingly being driven by the convergence of sophisticated therapeutic platforms, AI-enabled science, and the data infrastructure needed to move discoveries efficiently into development.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

• GSK is investing in a trispecific T-cell engager for multiple myeloma, with phase 1 development expected in 2027.
• Insilico is using AI and multiomics to advance longevity research and develop new approaches to measuring biological aging.
• Modern biopharma IT is increasingly centered on harmonized data, hybrid infrastructure, and AI-ready systems.